drugset / Trial / NCT05179421

Dose Ranging Study of Intravenous Oxytocin for Analgesia to Heat Pain

NCT05179421 ↗

Phase 2 Completed 25 enrolled Wake Forest University Health Sciences
RandomizedCrossoverTriple-blindBasic science

Summary

This is a study of participants that will receive intravenous (IV) infusions of oxytocin (naturally occurring hormone that is made by the brain). In this study healthy participants will be recruited for the study. There will be 3 study related visits: 1) screening and informed consent 2) study medication infusions and thermal heat testing 3) study medication infusions and thermal heat testing. During study visits 2 and 3 an IV catheter will be placed and a dose of oxytocin or placebo (inactive solution) will be given over a 10 minute period; 1 hour after the first infusion, a second 10 minute infusion of oxytocin will be administered. Investigators will perform some tests to evaluate how oxytocin changes perceptions of the skin. Investigators will study a painful perception by placing a probe on the skin of the side of lower leg and heating it up to 113-117 degrees Fahrenheit (F) (45-47 degrees Celsius (C)) for 5 minutes. Each participant will score any pain that is experienced on a 0 to 10 scale for each minute during the heating period. Most people find that pain rises during the 5 minutes, but remains mild; usually less than 5 on the 0 to 10 pain scale. The temperature of the 5 minute heating will be determined according to the participants pain rating during the screening visit. The primary objective of the study is to determine the dose response of IV oxytocin for analgesia (pain relief) to experimental heat pain.

Timeline

Start
2022-05-09
Primary completion
2023-02-10
Completion
2023-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 0.3 ug Intravenous
Subject Oxytocin Peptide 1.3 ug Intravenous
Subject Oxytocin Peptide 7 ug Intravenous

Indications

No indication recorded.